Wilson H. Jr Miller

Wilson H. Jr Miller's AcademicInfluence.com Rankings

Wilson H. Jr Miller

Philosophy

#7361

World Rank

#10565

Historical Rank

Logic

#4417

World Rank

#5706

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Wilson H. Jr Miller's Degrees

Doctorate Medicine Harvard University
PhD Immunology Stanford University

Why Is Wilson H. Jr Miller Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wilson H. Jr Miller's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (2011) (4157)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) (2647)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. (2015) (1780)
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML (1991) (1484)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1425)
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). (1991) (1261)
Role of the histone deacetylase complex in acute promyelocytic leukaemia (1998) (1126)
Mechanisms of action of arsenic trioxide. (2002) (961)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. (2020) (873)
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein (1994) (837)
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. (2004) (593)
Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. (1992) (448)
Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. (1993) (444)
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. (1998) (373)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. (2017) (367)
A review of cancer immunotherapy: from the past, to the present, to the future. (2019) (362)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. (2008) (328)
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). (1995) (321)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (294)
Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. (1994) (292)
All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study (1994) (288)
Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. (1992) (275)
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. (2009) (266)
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. (1994) (255)
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (2010) (249)
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. (2014) (246)
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. (2008) (238)
Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3 (2014) (218)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (216)
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. (2001) (204)
Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. (1993) (201)
CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. (1999) (199)
The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. (1996) (197)
Systemic cancer therapy: achievements and challenges that lie ahead (2013) (186)
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors (2009) (183)
Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines (2003) (167)
The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer (1998) (166)
A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. (1997) (162)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. (2015) (159)
The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation (2014) (159)
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. (2004) (156)
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results (2015) (155)
Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). (2016) (153)
The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function (2003) (147)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. (2019) (141)
Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors (2013) (141)
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. (2018) (141)
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. (1994) (140)
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. (2013) (133)
Moving towards personalized treatments of immune-related adverse events (2020) (132)
Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. (2017) (127)
Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors (2019) (126)
Clinical and Molecular Characterization of a Rare Syndrome of Acute Promyelocytic Leukemia Associated With Translocation (2002) (123)
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. (2019) (119)
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. (1994) (115)
Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells (2011) (115)
Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer (2011) (114)
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). (2013) (109)
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. (2011) (104)
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. (2001) (102)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (101)
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. (1995) (100)
Arsenic trioxide: mechanisms of action. (2002) (96)
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. (2008) (95)
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo (2005) (95)
9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia. (1995) (89)
Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. (1996) (86)
Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 (2019) (85)
High-Dose Intravenous Vitamin C Combined with Cytotoxic Chemotherapy in Patients with Advanced Cancer: A Phase I-II Clinical Trial (2015) (81)
Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. (1995) (80)
Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment (2007) (79)
Molecular targets of arsenic trioxide in malignant cells. (2002) (79)
Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. (1990) (77)
Retinoic acid induces down-regulation of several growth factors and proto-oncogenes in a human embryonal cancer cell line. (1990) (76)
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022) (76)
LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY (2014) (76)
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. (2005) (76)
Nuclear insulin receptor substrate 1 interacts with estrogen receptor α at ERE promoters (2004) (74)
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score (2011) (73)
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. (2015) (72)
Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis. (2015) (71)
Retinoids inhibit measles virus through a type I IFN‐dependent bystander effect (2009) (68)
Altered ligand binding and transcriptional regulation by mutations in the PML/RARalpha ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. (2000) (68)
Synergy between all-trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. (2003) (67)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. (2014) (66)
Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. (2002) (65)
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. (2017) (64)
Retinoic acid mediates degradation of IRS-1 by the ubiquitin–proteasome pathway, via a PKC-dependant mechanism (2004) (64)
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) (64)
Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils (2018) (63)
Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. (2002) (63)
Topoisomerase IIβ Negatively Modulates Retinoic Acid Receptor α Function: a Novel Mechanism of Retinoic Acid Resistance (2008) (61)
Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. (1994) (61)
A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment. (2015) (61)
A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E (2015) (60)
Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. (2003) (59)
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. (2003) (59)
Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. (1998) (58)
Astroglial cytoprotection by erythropoietin pre‐conditioning: implications for ischemic and degenerative CNS disorders (2005) (58)
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. (2008) (58)
Evaluation of denaturing high‐performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall‐cell lung cancer (2006) (57)
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma (2017) (57)
Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. (2004) (57)
The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy (2007) (56)
28-kDa Mammalian Heat Shock Protein, a Novel Substrate of a Growth Regulatory Protease Involved in Differentiation of Human Leukemia Cells (*) (1995) (55)
Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers (2010) (55)
Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling. (2006) (55)
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. (2014) (54)
Oxalic acid excretion after intravenous ascorbic acid administration. (2009) (54)
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study (2020) (54)
Retinoic acid causes a decline in TGF-alpha expression, cloning efficiency, and tumorigenicity in a human embryonal cancer cell line. (1990) (52)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. (2019) (50)
Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway (2003) (50)
Arsenic trioxide decreases AKT protein in a caspase-dependent manner (2008) (50)
Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. (2016) (49)
Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. (2013) (46)
Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. (1995) (46)
In vivo analysis of the role of aberrant histone deacetylase recruitment and RARα blockade in the pathogenesis of acute promyelocytic leukemia (2006) (44)
Trivalent Antimonials Induce Degradation of the PML-RAR Oncoprotein and Reorganization of the Promyelocytic Leukemia Nuclear Bodies in Acute Promyelocytic Leukemia NB4 Cells (1998) (43)
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study (2014) (43)
Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK (2004) (43)
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group (2005) (42)
Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. (1997) (41)
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. (2005) (41)
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer. (2016) (41)
405 POSTER Final results of a Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers (2007) (40)
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. (2014) (39)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. (2019) (38)
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2020) (37)
Aspartate 351 of Estrogen Receptor α Is Not Crucial for the Antagonist Activity of Antiestrogens* (2000) (37)
The N-terminal of the estrogen receptor (ERα) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells (2003) (37)
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. (2009) (36)
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines (2008) (36)
Predicted long‐term impact of COVID‐19 pandemic‐related care delays on cancer mortality in Canada (2021) (36)
1092PDAN UPDATE ON OVERALL SURVIVAL (OS) AND FOLLOW-ON THERAPIES IN BREAK-3, A PHASE III, RANDOMIZED TRIAL: DABRAFENIB (D) VS. DACARBAZINE (DTIC) IN PATIENTS (PTS) WITH BRAF V600E MUTATION-POSITIVE METASTATIC MELANOMA (MM). (2014) (36)
1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma (2017) (36)
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma (2017) (32)
Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation. (1990) (32)
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. (2009) (32)
Differentiation induction as a treatment for hematologic malignancies (2002) (32)
A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (31)
Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies (2019) (30)
Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells (1995) (30)
RIG-I Is Required for the Inhibition of Measles Virus by Retinoids (2011) (30)
Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis (2017) (30)
Regulation of myeloblastin messenger RNA expression in myeloid leukemia cells treated with all-trans retinoic acid. (1993) (30)
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. (2017) (29)
Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells. (2004) (29)
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma (2009) (29)
MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. (2019) (28)
Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial (1993) (27)
A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. (2011) (27)
ERbeta sensitizes breast cancer cells to retinoic acid: evidence of transcriptional crosstalk. (2004) (26)
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. (2009) (26)
Estrogen Receptor Expression Activates the Transcriptional and Growth-inhibitory Response to Retinoids without Enhanced Retinoic Acid Receptor α Expression (1998) (26)
Translation of cancer immunotherapy from the bench to the bedside. (2019) (25)
Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis (2013) (25)
Arsenic Trioxide Overcomes Rapamycin-Induced Feedback Activation of AKT and ERK Signaling to Enhance the Anti-Tumor Effects in Breast Cancer (2013) (25)
Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. (2008) (25)
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4 (2006) (24)
Probing the pathobiology of response to all-trans retinoic acid in acute promyelocytic leukemia: premature chromosome condensation/fluorescence in situ hybridization analysis. (1996) (24)
Adverse events associated with immune checkpoint inhibitor treatment for cancer (2019) (24)
Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America (2008) (24)
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). (2020) (24)
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity (2007) (24)
A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. (2017) (23)
The Novel Arsenical Darinaparsin Is Transported by Cystine Importing Systems (2014) (23)
Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. (2017) (23)
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (2017) (23)
Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. (2022) (23)
A ribozyme which discriminates in vitro between PML/RAR alpha, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RAR alpha, the transcripts from the nonrearranged alleles. (1994) (22)
Spatially mapping the immune landscape of melanoma using imaging mass cytometry (2022) (22)
Retinoic acid stimulates the protein kinase C pathway before activation of its beta-nuclear receptor during human teratocarcinoma differentiation. (1993) (22)
Targeting PKCδ-mediated topoisomerase IIβ overexpression subverts the differentiation block in a retinoic acid-resistant APL cell line (2010) (21)
High-dose vitamin C therapy: Renewed hope or false promise? (2006) (21)
All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas. (1994) (21)
The role of eIF4E in response and acquired resistance to vemurafenib in melanoma. (2015) (21)
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. (2007) (20)
The effect of 13-cis-retinoic acid on wound healing in dogs. (1987) (20)
Epidermal growth factor receptor mutations detected by denaturing high‐performance liquid chromatography in nonsmall cell lung cancer (2010) (20)
Molecular cytogenetics of the acute promyelocytic leukemia‐derived cell line NB4 and of four all‐trans retinoic acid–resistant subclones (2002) (19)
Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies (2011) (19)
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines (2009) (18)
The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma (2020) (18)
Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter (2007) (18)
Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (18)
Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates anti-tumor immune responses. (2021) (18)
Death by arsenic: implications of PML sumoylation. (2004) (17)
The biology of acute promyelocytic leukemia (2001) (16)
Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. (1995) (16)
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. (2003) (16)
Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells. (2000) (16)
1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA. (2014) (16)
A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. (2000) (16)
Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression. (1998) (15)
In vitro inhibition of mumps virus by retinoids (2013) (15)
The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells (2013) (15)
Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells (2017) (14)
The PML / RARa ! Oncoprotein Is a Direct Molecular Target of Retinoic Acid in Acute Promyelocytic Leukemia Cells (2002) (14)
The PML gene is linked to a megabase-scale insertion/deletion restriction fragment length polymorphism. (1995) (14)
Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. (1992) (14)
A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer. (2011) (13)
Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell. (1993) (13)
Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors (2018) (13)
Retinoic acid and its rearranged receptor in the etiology and treatment of acute promyelocytic leukemia. (1992) (13)
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). (2016) (13)
Role of PML/RARα in the pathogenesis of APL (2006) (13)
Expanding PML's functional repertoire through post-translational mechanisms. (2009) (13)
Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. (2011) (13)
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. (1993) (13)
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. (2014) (12)
Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid–sensitive and –resistant acute promyelocytic leukemia cells (2000) (12)
The MNK1/2–eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer (2021) (12)
Expression of SMRTbeta promotes ligand-induced activation of mutated and wild-type retinoid receptors. (2004) (12)
NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia. (2016) (12)
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer (2016) (12)
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade (2021) (11)
The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity (2017) (11)
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition (2022) (11)
Rexinoids Modulate Steroid and Xenobiotic Receptor Activity by Increasing Its Protein Turnover in a Calpain-dependent Manner* (2008) (11)
Hauschild A, Grob JJ, Demidov LV et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365 (2012) (10)
3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma (2015) (10)
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2). (2020) (10)
Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. (1994) (10)
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. (2014) (10)
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). (2014) (10)
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours (2013) (10)
Pulsed-field gel electrophoresis analysis of retinoic acid receptor-α and promyelocytic leukemia rearrangements : detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia (1993) (10)
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. (2019) (10)
Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. (2006) (9)
Pilot study of all-trans retinoic acid as post-remission therapy in patients with acute promyelocytic leukemia. (1995) (9)
An immunofluorescent assay for acute promyelocytic leukemia cells. (1998) (9)
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors (2021) (9)
A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors (2019) (9)
Molecular diagnosis and monitoring of acute promyelocytic leukemia treated with retinoic acid. (1994) (9)
The Etiology of Acute Leukemia (2013) (8)
Oncogenes and clinical oncology. (1991) (8)
SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study (2021) (8)
A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy. (2019) (8)
WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies. (2018) (7)
Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia. (2003) (6)
Expanding the Use of Retinoids in Acute Myeloid Leukemia: Spotlight on Bexarotene (2008) (6)
Retinoic acid and its rearranged receptor in the treatment of acute promyelocytic leukemia. (1993) (6)
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors (2022) (6)
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (6)
Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient (2012) (6)
Population-Based Study Detailing Cutaneous Melanoma Incidence and Mortality Trends in Canada (2022) (6)
A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors (2016) (6)
A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. (2020) (5)
NCIC CTG IND.122: a phase I/II pharmacokinetics (PK) and pharmacodynamic (PD) study of zd1839 (iressa ‘TM’). Final phase I results and preliminary phase II results of ZD1839 (750 mg/day) in patients (pts) with colorectal cancer (2001) (5)
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance (2021) (5)
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies (2005) (5)
Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients (2021) (5)
SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors. (2003) (5)
Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials (2014) (5)
291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors (2020) (4)
Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition (2020) (4)
795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 (2021) (4)
Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. (2011) (4)
Fecal microbiota transplantation followed by anti–PD-1 treatment in patients with advanced melanoma. (2022) (4)
Open-label, multicenter safety study of vemurafenib in patients with BRAFV600 mutation–positive metastatic melanoma. (2013) (4)
Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy (2007) (4)
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit (2021) (3)
Analysis of chromosome 12 abnormalities in male germ cell cancers. (1991) (3)
Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements (2021) (3)
Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. (2009) (3)
Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results. (2016) (3)
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. (2022) (3)
Predicted long-term impact of COVID-19 pandemic-related care delays on cancer incidence and mortality in Canada (2021) (3)
Perioperative bevacizumab (Bev) containing chemotherapy for colorectal liver metastases (2008) (3)
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation (2021) (3)
A Phase I Combination Study of Ribavirin and Low Dose Cytarabine Arabinoside (ara-C) in M4/M5 Acute Myeloid Leukemia (AML) and AML with High eIF4E, (2011) (3)
Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report (2021) (3)
Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy. (2019) (2)
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy (2022) (2)
A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer. (2020) (2)
131I-LABELED M195 FOR MYELOID LEUKEMIAS (1994) (2)
Abstract LB-171: A phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignancies (2010) (2)
A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. (2013) (2)
Cytokines and retinoic acid therapy for APL: new tricks from an old combination. (2004) (2)
Phase Ib study of sorafenib and vinorelbine as first-line treatment in patients with metastatic breast cancer. (2010) (2)
Prostate-Specific Membrane Antigen in the Diagnosis of Prostatic Carcinoma (1995) (2)
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors (2017) (2)
One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). (2015) (1)
Abstract 491: Selective killing of oncogenically transformed cells by arsenic trioxide and trolox (2014) (1)
Abstract 64: Quality and feasibility of a protocol for simultaneous isolation of RNA, DNA and tissue for IHC from needle core lymph node biopsies in DLBCL adapted for multi-center trials. (2013) (1)
Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines towards an ABC-like phenotype. (2022) (1)
166 Ho and 90 Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188 Re radiolabel (2017) (1)
Abstract 4707: Inhibition of autophagy overcomes acquired resistance to vorinostat (2012) (1)
WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies. (2017) (1)
Mechanisms of Action of Arsenic Trioxide Updated (2002) (1)
Pulsed-field gel electrophoresis analysis of retinoic acid receptor-alpha and promyelocytic leukemia rearrangements. Detection of the t(15;17) translocation in the diagnosis of acute promyelocytic leukemia. (1993) (1)
Growth factors in human germ cell cancer. (1991) (1)
In vitro inhibition of mumps virus by retinoids (2013) (1)
Abstract A154: Inhibition of eIF4E with Ribavirin suppresses EMT and breast cancer invasiveness. (2013) (1)
Resistance To Vorinostat In Hematological Malignancies May Involve Cytoprotective UPR and Correlates With Increased Sensitivity To Bortezomib-Induced Cell Death (2013) (1)
204 POSTER Recombinant IL-21 in combination with sorafenib as second or third-line therapy for metastatic renal cell carcinoma (mRCC): Interim results from a Phase 2 study (2008) (1)
Abstract B235: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to vemurafenib in melanoma. (2013) (1)
Molecular changes in epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) biopsies at time of progression compared to initial biopsy. (2016) (1)
Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (1)
Abstract A53: Phosphorylation of eIF4E promotes phenotype switching and MDSC-mediated immunosuppression in melanoma (2020) (1)
P4-249 Up-regulation of erythropoietin receptor expression in AD and MCI astroglia (2004) (1)
Transcriptional repression of the rara pathyway is crucial for leukemogenesis (2000) (0)
Phase II trial of sorafenib (S) and vinorelbine (V) in metastatic breast cancer (mBC) with pharmacokinetics (PK) analysis. (2012) (0)
P3.07 Building the Organization Framework for Biopsy-Driven Translational Research: The Quebec Clinical Research Organization in Cancer (Q-Croc) Experience (2012) (0)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial (2019) (0)
Abstract #5647: Enhancing mTORi efficacy by decreasing AKT feedback loop with arsenic trioxide (2009) (0)
Abstract B83: Combination therapy with the histone deacetylase inhibitor panobinostat and the CD20-targeting antibody rituximab in diffuse large B-cell lymphoma. (2011) (0)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (0)
Contents Vol. 78, 2010 (2010) (0)
Epidermal growth factor receptor (EGFR) mutations detected by denaturing high performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC): Correlation with disease stage and response to tyrosine kinase inhibitors (TKI) therapy (2008) (0)
74. Cross-coupling between the retinoic acid (RA) and protein kinase C (PKC) pathways potentiates RA-mediated human teratocarcinoma (TC) differentiation (1992) (0)
Epigenomic repression by APL oncoprotein (2008) (0)
The MNK1/2-eIF4E axis drives melanoma plasticity, progression, and resistance to immunotherapy (2020) (0)
P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma (2020) (0)
Abstract 1696: Targeting EVI1-overexpressing AML with darinaparsin (2012) (0)
Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in malignant cell lines (2005) (0)
Abstract LB-100: Optimal modulation of DNA repair in CLL therapy (2010) (0)
264 POSTER A novel arsenical, darinaparsin, induces apoptosis in arsenic trioxide-resistant and MRP1/ABCC1-overexpressing cell lines (2008) (0)
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (2017) (0)
Abstract A189: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors (2009) (0)
Abstract 4890: Arsenic trioxide induces apoptosis through the activation of ASK1 and is enhanced by a thioredoxin reductase inhibitor (2012) (0)
Abstract 5538: Development of HDACi resistance in DLBCL leads to a switch in subtype towards a more differentiated B-cell and is associated with increased sensitivity to proteasome inhibition (2014) (0)
The pleiotropic effects of the MNK1/2-eIF4E axis support immune suppression and metastasis in a model of postpartum breast cancer (2020) (0)
Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer. (2023) (0)
Abstract 3710: The role of eIF4E in promoting melanoma cell proliferation and maintaining acquired resistance to Vemurafenib in melanoma (2014) (0)
Subject Index Vol. 78, 2010 (2010) (0)
Technology & tools development (2012) (0)
Use of denaturing high performance liquid chromatography (dHPLC) for detection of EGFR mutations in patients with NSCLC. (2006) (0)
Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation (2023) (0)
Novel Transcriptional Interactions Between the Estrogen and Retinoic Acid Receptors in Human Breast Cancer Cells (2000) (0)
The role of Ki-67 proliferation index vis-à-vis Oncotype DX. (2011) (0)
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma (2021) (0)
Darinaparsin a Novel Organic Arsenic Molecule Active in Lymphoma: Development of An Oral Form. (2009) (0)
apoptosis in APL and other malignant cell lines Trolox selectively enhances arsenic-mediated oxidative stress and (2013) (0)
Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP). (2018) (0)
Abstract A188: Proapoptotic versus prosurvival function of the MAP kinase p38 induced by HDAC inhibitor in hematological malignant cells (2009) (0)
Abstract S12-01: High mortality among hospital-acquired COVID-19 infection in patients with cancer: An observational cohort study from Quebec and British Columbia (2020) (0)
Targeting EVI1-Overexpressing AML with Darinaparsin (2011) (0)
Abstract 5360: Differential induction of the anti-oxidant response by arsenic trioxide and darinaparsin in leukemic cells (2011) (0)
O-086 A phase III randomized trial of carboplati/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) (2005) (0)
A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study. (2007) (0)
Supplemental Information NPM and BRG 1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia (2016) (0)
A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1 (2013) (0)
Abstract 686: MNK1 promotes the progression of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) (2016) (0)
Prognostic signiﬁcance of minimal residual disease detection and PML/RAR- a isoform type: long-term follow-up in acute promyelocytic leukemia (2001) (0)
Abstract 2706: Phase 2 study with pharmacokinetics (PK) analysis of sorafenib and vinorelbine in metastatic breast cancer (2012) (0)
Abstract 857: Anti-tumor and anti-metastatic activity of the eIF4E-targeted drug ribavirin in human and murine models of breast cancer. (2013) (0)
Abstract A146: The role of cystine transport in darinaparsin‐induced cell death (2009) (0)
961P Genomic and transcriptomic profiling in head and neck tumours to identify treatment options: The WINTHER trial experience (2020) (0)
Optimized protocol for immunophenotyping of melanoma and tumor-bearing skin from mouse (2021) (0)
Uveal melanoma: Real-world analysis of immune checkpoint inhibitors efficacy and lymphocyte-to-monocyte ratio as a biomarker of response. (2022) (0)
Abstract 2136: Expression of fusion proteins in acute myeloid leukemia cells increases sensitivity to histone deacetylase inhibitors (2011) (0)
Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene mutations detected by denaturing high-performance liquid chromatography (dHPLC) in non-small cell lung cancer (NSCLC) (2007) (0)
Abstract 942: Decreasing the AKT feedback loop with arsenic trioxide enhances mTORi anti-tumor effects. (2013) (0)
The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses (2022) (0)
Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors. (2018) (0)
P19 A novel way of assessing health and vulnerability in older newly-diagnosed cancer patients: results of a pilot study (2009) (0)
Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience (2012) (0)
Trolox Improves the Sensitivity of Multiple Myeloma to Arsenic Trioxide in Vitro and In Vivo. (2009) (0)
113. Reverse transcription polymerase chain reaction (RT-PCR) for the rearranged retinoic acid receptor-α (RAR-α) predicts response of acute promyelocytic leukemia (APL) to retinoic acid (RA) therapy and detects minimal residual disease (1992) (0)
Author response: The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity (2017) (0)
Abstract 288: TGF-beta induced epithelial-to-mesenchymal transition is attenuated when the MNK/eIF4E pathway is functionally impaired. (2013) (0)
Abstract 5449: Histone deacetylase inhibitor treatment in B-cell non-Hodgkin's lymphoma - effect ofex vivotreatment on primary patient samples (2010) (0)
Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM) (2015) (0)
171. Clinical and pharmacologic aspects of all-trans retinoic acid treatment in acute promyelocytic leukemia (1992) (0)
RAPID COMMUNICATION Continuous Treatment With All-Trans Retinoic Acid Causes a Progressive Reduction in Plasma Drug Concentrations: Implications for Relapse and Retinoid “Resistance” in Patients With Acute Promyelocytic Leukemia (2003) (0)
Abstract IA09: Translational control of the tumor microenvironment (2017) (0)
1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
Darinaparsin:anovelorganic arsenicalwithpromising anticanceractivity (2009) (0)
Abstract 3165: Anti-tumor activity of the eIF4E-targeted drug ribavirin in breast cancer cells (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wilson H. Jr Miller?

Wilson H. Jr Miller is affiliated with the following schools:

McGill University
University of Manchester